kisspeptin vs kisspeptin 10: Frequently asked questions

Use kisspeptin-10. Its rapid onset (peak LH at 20–30 minutes post-injection) and short half-life mean you're capturing the acute response without confounding from prolonged receptor occupancy that would blur your sampling window. Kisspeptin-54's slower kinetics would still be releasing GnRH at your 60-minute timepoint, making it harder to distinguish first-phase from sustained-phase LH secretion.

Kisspeptin-54 or a modified long-acting analogue is preferable. The extended half-life reduces the infusion rate required to maintain steady-state plasma levels, which matters both for peptide cost and for minimising injection-site reactions in animal models. Kisspeptin-10's 4–6 minute half-life would require near-constant infusion to avoid pulsatile rather than tonic GnRH stimulation.

Discard it. Peptides with C-terminal amidation are susceptible to deamidation at temperatures above 8°C, and once that protective amide group is lost, receptor binding drops by 90% or more. There is no reliable way to test potency without a bioassay, so any temperature excursion during storage invalidates the batch for dose-response studies.

Check for hypothalamic-pituitary suppression from other sources first. Kisspeptin requires functional GnRH neurons and responsive pituitary gonadotrophs. If the animal has been pre-treated with a GnRH antagonist, if it's in seasonal anoestrus, or if chronic stress has downregulated KISS1R expression, exogenous kisspeptin will produce blunted or absent LH release regardless of dose. Dose escalation beyond 4 nmol/kg typically doesn't overcome true receptor desensitisation.

Recalculate your effective dose immediately and adjust subsequent injections. A 10 µg dose of kisspeptin-10 delivers approximately 7.7 nmol, whereas 10 µg of kisspeptin-54 delivers only 1.7 nmol. A 4.5-fold molar difference. If you dosed kisspeptin-54 at 10 µg expecting kisspeptin-10-level GnRH stimulation, you've undershot the molar target by more than 75%. The result will be attenuated LH release and potentially insufficient GnRH neuron activation. Re-dose at the corrected molar concentration and document the error for your experimental records. This is a common mistake when switching peptides mid-study.

First, verify peptide integrity and reconstitution method. Kisspeptin-10 stored as lyophilized powder at −20°C remains stable for 12+ months, but once reconstituted in sterile water or saline, it must be used within 7–10 days when refrigerated at 2–8°C. Repeated freeze-thaw cycles degrade the peptide structure. Particularly at the N-terminal tyrosine and internal tryptophan residues. Rendering it inactive. If your reconstituted stock has been frozen and thawed more than twice, prepare a fresh aliquot. Second, confirm injection timing relative to the animal's reproductive cycle. GnRH neurons in certain reproductive states (e.g., anestrus, prepubertal) show blunted kisspeptin responsiveness due to altered KISS1R expression or downstream signaling pathway desensitization.

Design a pulse-dosing schedule with injections every 60–90 minutes to approximate continuous receptor stimulation. Kisspeptin-10's 30-minute half-life means plasma concentrations fall below the receptor activation threshold (typically 1–2 nM) within 90–120 minutes of a single bolus. For a 6-hour sustained-stimulation window, administer 1–2 nmol/kg every 75 minutes. Four doses total. Monitor cumulative receptor desensitization by measuring LH response to the final dose; if LH release drops below 50% of the initial response, KISS1R downregulation has occurred and longer inter-dose intervals (120 minutes) may be required. Alternatively, consider incorporating kisspeptin-54 or a slow-release delivery system if the protocol extends beyond 12 hours.